Please use this identifier to cite or link to this item:
Authors: Schultheis, Michael
Staubach, Petra
Grabbe, Stephan
Ruckes, Christian
Stetbut, Esther von
Kirschner, Uwe
Matusiak, Łukasz
Szepietowski, Jacek C.
Nikolakis, Georgios
Title: LAight® therapy is an effective treatment option to maintain long-term remission of Hurley I and II Hidradenitis Suppurativa: results from period B of RELIEVE, a multicenter randomized, controlled trial
Online publication date: 19-Apr-2023
Year of first publication: 2022
Language: english
Abstract: Background: Hidradenitis suppurativa is a chronic, inflammatory, burdensome skin disease where current first-line treatments are limited to topical and/or systemic antibiotics which cannot be applied for long-term disease management. Period B of the RELIEVE study analyzes whether LAight® therapy can sustain or even increase remission after a first topical antibiotic treatment cycle. Methods: The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating Hurley I and II patients were randomized to either a group receiving topical clindamycin 1% solution combined with 8 additional bi-weekly treatments with LAight® therapy (group TC + L) or a group which was treated with topical clindamycin 1% solution only (group TC). After 16 weeks, patients entered open-label period B and both groups were treated exclusively with LAight® therapy for an additional 16 weeks (8 sessions, group TC + L/L and group TC/L). Results: In total, 88 patients were enrolled in RELIEVE. Seventy-eight patients entered period B; 39 belonged to group TC + L/L and 39 to group TC/L. The IHS4-response at the start of period B was 62% (group TC + L/L) and 33% (group TC + L). During the 16 weeks of additional monotherapy with LAight, in both groups >90% of patients who responded to therapy in period A maintained their IHS4-response at week 32. IHS4 response rates continued to rise up to 79% of the TC + L/L group and up to 71% of the TC/L group during period B at week 32. Achievement of HiSCR and certain patient reported outcomes confirmed primary endpoint results. Conclusion: LAight® therapy is an effective approved therapy option for Hurley I and II HS that can be used continuously to maintain treatment success. During 16 weeks of follow-up in period B, over 90% of patients with response after period A maintained their treatment outcome, while more than 60% of prior nonresponders gained response. The fact that LAight® therapy can be applied continuously, is very effective and is well tolerated makes it a valuable treatment tool in the design of HS long- term treatment modalities.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
Document type specification: Scientific article
License: CC BY
Information on rights of use:
Journal: Dermatology
Pages or article number: 1092
Publisher: Karger
Publisher place: Basel ; Freibung [Breisgau] ; Paris ; London ; New York ; Bangalore ; Bankok ; Singapore ; Tokyo ; Sydney
Issue date: 2022
ISSN: 1421-9832
Publisher DOI: 10.1159/000524739
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
laight®_therapy_is_an_effecti-20230227091250479.pdf701.43 kBAdobe PDFView/Open
laight®_therapy_is_an_effecti-20230227091303292.pptx419.1 kBMicrosoft Powerpoint XMLView/Open